Issue Open Date
|
27-Jul-21
|
Issue Closing Date
|
29-Jul-21
|
Application Money
|
100
|
Allotment Money
|
|
|
Price Band
|
695
-
720
|
Minimium Application No.
|
20
|
Issue Size (Shares)
|
21022222
|
Market Lot
|
1
|
|
|
Objective
|
1. Payment of outstanding purchase consideration to the Promoter for the spin-off of the API business from the Promoter into our Company pursuant to the Business Purchase Agreement.2. Funding capital expenditure requirements.3. General corporate purposes.
|
|
|
|
Category
|
No. of Shares
|
No. of Shares
|
Subscription Ratio
|
|
Offered / Reserved |
Bid For |
|
Non-Institutional Investors
|
3232770
|
396129640
|
122.535670647773
|
Qualified Institutional Buyers
|
4242379
|
156829300
|
36.9673006584277
|
Retail Individual Investors
|
4242379
|
156829300
|
36.9673006584277
|
|
|
|
Business Description
We are a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (“APIs”) in chronic therapeutic areas, including cardiovascular disease (“CVS”), central nervous system disease (“CNS”), pain management and di
|
|
Promoter's Holding
|
Total Share Capital
|
131567217
|
Offered to Public
|
21022222
|
Promoter's Holding (Pre-Issue)
|
46.63
|
Promoter's Holding (Post-Issue)
|
82.84
|
|
MORE > |
|
|
|
|
|
Address |
Plot No. 170-172 Chandramouli Industrial Estate Mohol Bazarpeth
Solapur
,
Maharashtra
,
413213
Phone :
02189 234456/234246
Email :
complianceofficer@glenmarklifesciences.com
Website :
www.glenmarklifesciences.com
|
|
Registrar |
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B Plot 31-32 Gachibowli Financial District Nanakramguda Hyderabad
|
|
Listed at |
BSE, NSE
|
|
Lead Manager |
BOB Capital Markets Ltd BofA Securities India Ltd. Dam Capital Advisors Ltd. (Formerly IDFC Securities Ltd.) Goldman Sachs (India) Securities Pvt Ltd Kotak Mahindra Capital Co Ltd SBI Capital Markets Ltd
|
|
Promoters |
Glenmark Pharmaceuticals Ltd
|
|